These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 29712686)
1. CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia. Ajiro M; Sakai H; Onogi H; Yamamoto M; Sumi E; Sawada T; Nomura T; Kabashima K; Hosoya T; Hagiwara M Clin Cancer Res; 2018 Sep; 24(18):4518-4528. PubMed ID: 29712686 [No Abstract] [Full Text] [Related]
2. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells. Jiang B; Xue M Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278 [TBL] [Abstract][Full Text] [Related]
3. Distribution of human papillomavirus 16 E6/E7 variants in cervical cancer and intraepithelial neoplasia in Chinese women. Ding T; Wang X; Ye F; Cheng X; Lu W; Xie X Int J Gynecol Cancer; 2010 Nov; 20(8):1391-8. PubMed ID: 21051983 [TBL] [Abstract][Full Text] [Related]
4. Genetic variability and functional implication of HPV16 from cervical intraepithelial neoplasia in Shanghai women. Zhao J; Zhu J; Guo J; Zhu T; Zhong J; Liu M; Ruan Y; Liao S; Li F J Med Virol; 2020 Mar; 92(3):372-381. PubMed ID: 31670402 [TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway. Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701 [TBL] [Abstract][Full Text] [Related]
6. Distribution of human papillomavirus type 16 E6 and E7 gene variants in the progression of cervical dysplasia in Korean women. Lee CW; Bae JH; Lee SJ; Ho EM; Lee IH; Park YG; Park JS J Obstet Gynaecol Res; 2011 Oct; 37(10):1320-6. PubMed ID: 21535311 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system. Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665 [TBL] [Abstract][Full Text] [Related]
8. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Li B; Hu Y; Ye F; Li Y; Lv W; Xie X Int J Gynecol Cancer; 2010 May; 20(4):597-604. PubMed ID: 20442590 [TBL] [Abstract][Full Text] [Related]
9. Individual and Complementary Effects of Human Papillomavirus Oncogenes on Epithelial Cell Proliferation and Differentiation. Bergner S; Halec G; Schmitt M; Aubin F; Alonso A; Auvinen E Cells Tissues Organs; 2016; 201(2):97-108. PubMed ID: 26636751 [TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia. Sathish N; Abraham P; Peedicayil A; Sridharan G; John S; Chandy G Mol Diagn; 2004; 8(1):57-64. PubMed ID: 15230643 [TBL] [Abstract][Full Text] [Related]
11. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Melsheimer P; Vinokurova S; Wentzensen N; Bastert G; von Knebel Doeberitz M Clin Cancer Res; 2004 May; 10(9):3059-63. PubMed ID: 15131043 [TBL] [Abstract][Full Text] [Related]
12. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer. Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680 [TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer. Munagala R; Aqil F; Jeyabalan J; Gupta RC Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375 [TBL] [Abstract][Full Text] [Related]
14. Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer. Zhang JJ; Cao XC; Zheng XY; Wang HY; Li YW J Int Med Res; 2018 Mar; 46(3):1033-1042. PubMed ID: 29322839 [TBL] [Abstract][Full Text] [Related]
15. Prediction of human papillomavirus 16 e6 gene expression and cervical intraepithelial neoplasia progression by methylation status. Hublarova P; Hrstka R; Rotterova P; Rotter L; Coupkova M; Badal V; Nenutil R; Vojtesek B Int J Gynecol Cancer; 2009 Apr; 19(3):321-5. PubMed ID: 19407553 [TBL] [Abstract][Full Text] [Related]
16. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3. Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046 [TBL] [Abstract][Full Text] [Related]
17. HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. Cardeal LB; Boccardo E; Termini L; Rabachini T; Andreoli MA; di Loreto C; Longatto Filho A; Villa LL; Maria-Engler SS PLoS One; 2012; 7(3):e33585. PubMed ID: 22438955 [TBL] [Abstract][Full Text] [Related]
18. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line. Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640 [TBL] [Abstract][Full Text] [Related]
19. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells. Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692 [TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]